ReviewInternational journal of molecular sciences2021
Peptides to Tackle Leishmaniasis: Current Status and Future Directions.
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 32 citations in OpenAlex.
- Assessing Designed Model Membrane-Targeting Peptides Found as Potential Molecular Scaffolds against Cutaneous Leishmaniasis.ACS omega · 2026Article
- Peptides as a Therapeutic Alternative Against Leishmaniasis: A Scoping Review.Chemical biology & drug design · 2026Article
- Animal Venoms as Peptide Libraries for the Discovery of Antiglioblastoma Agents.Biochemistry research international · 2026Review
- Exploring the mechanisms of action of the antimicrobial peptide CZS-5 against Trypanosoma cruzi epimastigotes: insights from metabolomics and molecular dynamics.Parasites & vectors · 2025Article
- A novel inhibitory strategy ofFuture microbiology · 2025Article
- The Potential Use of Peptides in the Fight against Chagas Disease and Leishmaniasis.Pharmaceutics · 2024Review
- Neglected Zoonotic Diseases: Advances in the Development of Cell-Penetrating and Antimicrobial Peptides against Leishmaniosis and Chagas Disease.Pathogens (Basel, Switzerland) · 2023Review
- Evaluation of the antileishmanial effect of polyclonal antibodies and cationic antimicrobial peptides.Pathogens and global health · 2023Article
- Unrevealing the Mystery of Latent Leishmaniasis: What Cells Can HostPathogens (Basel, Switzerland) · 2023Review
- Repurposing the Antibacterial Agents Peptide 19-4LF and Peptide 19-2.5 for Treatment of Cutaneous Leishmaniasis.Pharmaceutics · 2022Article
- Bioactive Peptides against Human Apicomplexan Parasites.Antibiotics (Basel, Switzerland) · 2022Review
- Bioactive Antimicrobial Peptides: A New Weapon to Counteract Zoonosis.Microorganisms · 2022Review
- Metabolic Pathways ofPharmaceutics · 2022Review
- Traditional and Computational Screening of Non-Toxic Peptides and Approaches to Improving Selectivity.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Lessons from a Single Amino Acid Substitution: Anticancer and Antibacterial Properties of Two Phospholipase ACurrent issues in molecular biology · 2021Article
- Small Molecule-Peptide Conjugates as Dimerization Inhibitors ofPharmaceuticals (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 3 countries.
Funding
Abstract
Peptide-based drugs are an attractive class of therapeutic agents, recently recognized by the pharmaceutical industry. These molecules are currently being used in the development of innovative therapies for diverse health conditions, including tropical diseases such as leishmaniasis. Despite its socioeconomic influence on public health, leishmaniasis remains long-neglected and categorized as a poverty-related disease, with limited treatment options. Peptides with antileishmanial effects encountered to date are a structurally heterogeneous group, which can be found in different natural sources-amphibians, reptiles, insects, bacteria, marine organisms, mammals, plants, and others-or inspired by natural toxins or proteins. This review details the biochemical and structural characteristics of over one hundred peptides and their potential use as molecular frameworks for the design of antileishmanial drug leads. Additionally, we detail the main chemical modifications or substitutions of amino acid residues carried out in the peptide sequence, and their implications in the development of antileishmanial candidates for clinical trials. Our bibliographic research highlights that the action of leishmanicidal peptides has been evaluated mainly using in vitro assays, with a special emphasis on the promastigote stage. In light of these findings, and considering the advances in the successful application of peptides in leishmaniasis chemotherapy, possible approaches and future directions are discussed here.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.